Health
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
- Medications’ revenue to reach $70 billion in the US alone
- Eli Lilly stands to dominate US market into the 2030s
Boxes of Ozempic at pharmacy counter in Los Angeles, California.
Photographer: Mario Tama/Getty ImagesThis article is for subscribers only.
The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.
That’s according to BMO Capital Markets analyst Evan David Seigerman, who, in a note to clients late Thursday, also said revenue for the medications could reach as high as $70 billion in the US alone.